Discovery Life Sciences has acquired ReachBio Research Labs, a Seattle-based contract research organization (CRO). This acquisition will allow Discovery Life Sciences to scale its consolidated drug discovery and preclinical development offerings to give customers access to a broader range of specialized cell biology services. Financial terms of the deal were not disclosed.
ReachBio Research Labs specializes in cell-based assays, predictive hematotoxicity and drug screening services. The company provides primary cell biology-based contract research services and products to the drug development and life science research communities.
Founded in 2018, Discovery Life Sciences provides biospecimen analysis, procurement and distribution for the pharmaceutical, biotechnology and diagnostics industries.
In July 2022, Discovery Life Sciences acquired AllCells to create one of the industry’s largest dedicated client donor pools. AllCells is dedicated to providing global researchers and biomanufacturing organizations with a supply of clinical-grade (GMP-compliant) and research use only primary cell products.
According to data captured in the LevinPro HC database, this represents the 12th CRO acquisition of 2023. This is an increase from 2022 when there were ten CRO transactions announced between January 1, 2022, and April 12, 2022.
